Kühne Holding Acquires Aenova from BC Partners

Kühne Holding has agreed to purchase Aenova Group, a pharma contract development and manufacturing organization (CDMO), from BC Partners. BC will reinvest and retain a minority stake in Aenova. The financial terms remain undisclosed.

Aenova Group, a global CDMO headquartered in Starnberg, provides comprehensive services for the development, manufacturing, and packaging of drug products. With 4,000 employees across 14 sites, it has grown into one of the world’s top ten CDMOs under BC Partners’ ownership and CEO Jan Kengelbach’s leadership. In 2023, Aenova achieved record pro-forma revenue of € 832m, up 17% from the previous year.

Dominik de Daniel, CEO at Kühne Holding, commented, "With this investment, we are taking an important strategic step to enlarge our investment portfolio to include healthcare and pharmaceutical assets with a strong financial base and long-term growth prospects. Aenova Members of the Aenova Group C.P.M. - CPR - Dragenopharm - Haupt Pharma - Swiss Caps - SwissCo - Temmler is on a great performance track, and we are excited to accelerate it even further under our ownership."

BC Partners’ Chairman, Raymond Svider, added, “We’re pleased to see such an important German healthcare business continue its growth trajectory under the strategic ownership of Kühne Holding AG. As a firm, we have a long and successful history of partnering with families and founders across Europe, and we look forward to working closely with Kühne Holding and Aenova in this next chapter for the business.”

Jan Kengelbach, CEO at Aenova, said, "With the new ownership structure, we will continue to implement our strategy of making Aenova the go-to CDMO with market-leading capabilities and innovative specialty technologies in Europe. With its long-term investment horizon, Kühne Holding is a perfect fit for the business to support this strategy. It allows us to continue down the path of operational excellence in the conventional manufacturing business, while building highly sought-after technology platforms and development services to satisfy the customer demand of the future."

Kühne Holding acquires pharma contract manufacturer Aenova from BC Partners....
Kühne Holding acquires pharma contract manufacturer Aenova from BC Partners. © Aenova Group

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.